Personalized cell therapies show more promise in solid tumors – Medical Xpress
Medical Xpress |
Personalized cell therapies show more promise in solid tumors
Medical Xpress Last year, O’Rourke and his colleagues reported that these CAR T cells successfully migrated to and infiltrated GBM tumors in nine patients, which has been an ongoing challenge in the treatment of many solid tumors with CAR because of an unfavorable … |
Memorial Sloan Kettering Cancer Center (blog) |
Blood Will Tell: Scientists Find Clues to Immunotherapy Responders and Non-Responders
Memorial Sloan Kettering Cancer Center (blog) Some patients who receive immunotherapy drugs called checkpoint inhibitors experience significant benefit in terms of tumor shrinkage and longer survival — but many do not. A new study suggests that measuring changes in the blood could help doctors … Do We Need Biomarkers to Predict Tumor Hyper-Progression Following Immunotherapy?AJMC.com Managed Markets Network Long term benefits of immunotherapy emerging for some patients, though key questions remainCancer Research UK Matching tumor size to strength of immune response allows melanoma drug tailoringEurekAlert (press release) |
|
The media, synthetic biology and CRISPR – fears vs. reality
BioNews A recent Wall Street Journal article, ‘DIY Gene Editing: Fast, Cheap – and Worrisome’, describes the Saturday afternoon of teenager, Kian Sadeghi, as he learns to use CRISPR/Cas9 at the Genspace Community Lab in Brooklyn, New York. Like many news … |
Quartz |
A new sci-fi thriller about CRISPR makes gene editing terrifyingly easy to understand
Quartz The webbed world we live in now would have seemed like science fiction not long ago. Thriller writer Daniel Suarez believes that coming changes will be much more dramatic. He predicts that by 2045 bespoke babies—plus pets, plants, bacteria, and … |